Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DVxTSE:3079 45 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates TSE:3079 with a GF Score™ of 45/100 and a GF Value™ of 円1,225.14 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 699 Medical Devices & Instruments companies, DVx ranks worse than 143061.37% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for DVx's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of DVx was 0.02. The lowest was 0.00. And the median was 0.00.
TSE:3079's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.24 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
DVx Debt-to-Equity Related Terms
DVx Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for DVx's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3079 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, DVx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DVx Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DVx's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where DVx's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVx (TSE:3079) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DVx and its competitors. According to the industry distribution chart, DVx ranks #999999 out of 699 companies in the Medical Devices & Instruments industry.
Is DVx's Debt-to-Equity too high?
DVx's current Debt-to-Equity is 0.00. Based on the distribution chart, DVx ranks #999999 out of 699 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, DVx has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DVx's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, DVx ranks #999999 out of 699 companies for Debt-to-Equity. This places DVx in the lower half of its industry. The industry median Debt-to-Equity is 0.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DVx and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DVx's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DVx stock overvalued right now?
Based on GuruFocus' analysis, DVx (TSE:3079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,225.14, compared to a current price of 円930.00 — trading 24.1% below its estimated fair value. The current Debt-to-Equity is 0.00. DVx's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For DVx (TSE:3079), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DVx (TSE:3079) Overvalued in 2026?
Based on GuruFocus' analysis, DVx stock appears to be undervalued.
The current stock price of 円930.00 is trading 24.1% below its estimated GF Value™ of 円1,225.14.
GuruFocus considers DVx to be Modestly Undervalued.
Key valuation signals for TSE:3079:
Debt-to-Equity: 0.00
GF Value™: 円1,225.14 vs. price of 円930.00 (24.1% below fair value)
No single metric tells the full story. See the TSE:3079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DVx Inc is engaged in manufacture, sale, repair, and leasing of medical equipment and related peripheral equipment, research and development of medical equipment, provide in house and out of service consulting services and services for medical and medical devices, and providing medical publication and market research.
45GF Score
Get the complete analysis for TSE:3079
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3079 has been successfully added to your 
